Verdiperstat

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameVerdiperstat
Drug Alias NameBHV-3241AZD-3241
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMyeloperoxidase inhibitors
TargetsMyeloperoxidase
Therapy Area/IndicationsFrontotemporal DementiaParkinson DiseaseMultiple System Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenItaly +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthBiohaven Asia Pacific LtdBiohaven Pharmaceuticals Inc +[4] 
Inactive CompaniesAstrazeneca PlcRecipharm Pharmaservices Pvi LtdBiohaven New Management (Shanghai) Co Ltd
Active IndicationsFrontotemporal DementiaMultiple System Atrophy
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A